Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1.
We demonstrate that soluble CD16 (sCD16; soluble Fc gamma RIII), a natural ligand of CR3, inhibits the infection of monocytes by primary R5 HIV-1 strain opsonized with serum of seronegative individuals. Inhibition of monocyte infection by sCD16 was similar to that observed with anti-CR3 mAbs, indicating that opsonized HIV may use a CR3-dependent pathway for entry in monocytic cells. Cultured human monocytes express both CR3 (CD11b/CD18) and CCR5 receptors. RANTES, the natural ligand of CCR5, inhibited infection of monocytes with unopsonized HIV particles and partially that of monocytes infected with HIV particles opsonized with complement-derived fragments. Although HIV-infected monocytes from homozygous CCR5 Delta 32/Delta 32 (CCR5(-/-)) individuals produce low levels of p24, cells infected with opsonized particles produced higher levels of p24 than cells infected with unopsonized particles. Our results thus suggest that CR3 may represent an alternative coreceptor to CCR5 of opsonized primary R5 virus entry into monocytes/macrophages. We also observed that the concentration of sCD16 is greatly decreased in sera of HIV-infected patients with low lymphocyte CD4(+) counts. Taken together, our findings suggest that sCD16, present in plasma, may play an important role in controlling HIV-1 spread.
Bouhlal
H
H
Institut National de la Santé et de la Recherche Médicale Unité 430, Hôpital Broussais, Paris, France.
Galon
J
J
Kazatchkine
M D
MD
Fridman
W H
WH
Sautès-Fridman
C
C
Haeffner Cavaillon
N
N
D000276:Adjuvants, Immunologic / Q000097:blood / Q000502:physiology; D000818:Animals; D000998:Antiviral Agents / Q000097:blood / Q000276:immunology*; D018821:CD18 Antigens / Q000502:physiology*; D002460:Cell Line; D002478:Cells, Cultured; D006224:Cricetinae; D015658:HIV Infections / Q000097:blood / Q000276:immunology; D015497:HIV-1 / Q000276:immunology* / Q000378:metabolism / Q000472:pathogenicity; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000276:immunology; D016177:Macrophage-1 Antigen / Q000502:physiology*; D008264:Macrophages / Q000276:immunology* / Q000821:virology; D009000:Monocytes / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D009895:Opsonin Proteins / Q000097:blood / Q000276:immunology*; D019713:Receptors, CCR5 / Q000172:deficiency / Q000235:genetics; D017452:Receptors, IgG / Q000097:blood / Q000502:physiology*; D012995:Solubility
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D018821:CD18 Antigens; D007166:Immunosuppressive Agents; D016177:Macrophage-1 Antigen; D009895:Opsonin Proteins; D019713:Receptors, CCR5; D017452:Receptors, IgG